Recursion Pharmaceuticals Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.94 (market cap $2.03B). The key difference: Recursion Pharmaceuticals Inc and Direxion Daily 20 Year Treasury Bull 3X Shares are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| RXRX | TMF | |
|---|---|---|
Market Cap | $2.14B | $2.03B |
Volume | 30,789,535 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $6.79 | $44.14 |
52-Week Low | $2.84 | $25.19 |
Typical Hold Time | 22 Days | 28 Days |
Enterprise Value | $1.66B | — |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.64 with a 1.61% daily gain amid elevated volume. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators are neutral. The ETF saw increased trading activity with over 5.2 million shares changing hands, as reported by Defense World on October 3, 2026. A dividend of $0.35 is scheduled for payment on September 29, 2026.
The outlook for TMF remains tied to long-term Treasury bond performance, with current technical weakness suggesting near-term pressure. Investment opportunity exists for investors bullish on declining long-term interest rates, but risks include interest rate volatility and the leveraged nature of the ETF amplifying losses. Market sentiment appears mixed given conflicting technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →